Navigation Links
Nile Therapeutics Provides Update on Ongoing Phase I Clinical Trial of Cenderitide
Date:6/27/2011

SAN MATEO, Calif., June 27, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has completed dosing the first patient in Part B of the ongoing Phase I study. Part B involves dosing cenderitide with Medtronic's insulin pump technology. The trial is being conducted pursuant to Nile's previously announced collaboration with Medtronic and is the first clinical step towards developing cenderitide as a 90-day outpatient treatment for heart failure patients following admission for acutely decompensated heart failure (ADHF), referred to as the "post-acute" treatment period. This program was recently granted Fast Track status by the United States Food and Drug Administration (FDA).

"In Part A, we evaluated the pharmacokinetics of administering cenderitide through subcutaneous bolus injection," said Hsiao Lieu, MD, Vice President of Clinical Research at Nile. "We congratulate our investigators and our research partners for their outstanding efforts to complete Part A so quickly. We were very pleased with pharmacokinetics, bioavailability and safety of the subcutaneous bolus injection of cenderitide. We expect to achieve our primary objective, which is to determine the subcutaneous dose rates for future clinical studies."

The Phase I clinical trial, which began in April, 2011, is a placebo-controlled study evaluating pharmacokinetic and pharmacodynamic actions of cenderitide when administered to chronic heart failure patients as a subcutaneous infusion or as a subcutaneous bolus injection. The trial is designed to understand the doses required to achieve pre-determined plasma levels of cenderitide when delivered through a subcutaneous infusion pump. In Part A of the trial, patients received two subcutaneous bolus injections of cenderitide.  In Part B of the trial, patients will receive a 24 hour continuous infusion of either cenderiti
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
4. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
5. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
6. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
7. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Arno Therapeutics Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... The ability for organizations to attract top ... individuals to perform at the highest of levels, are ... to compete in this post–recession era. The pharmaceutical ... the sector increasingly focuses on the importance of employee-fit ... real results on the organization's development and the innovation ...
(Date:8/28/2014)... Exciting new work by a Florida State University ... that can take your temperature, emit white light, and ... the molecule looks like a butterfly. , Biwu Ma, ... Engineering in the FAMU-FSU College of Engineering, created the ... has continued to discover that his creation has many ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Supplementing ... offering a promotion for Eppendorf Safe Lock ... to purchase the highest quality tubes at an ... ideal for customers doing chemical, medical, pharmaceutical, and ... who are not regularly able to afford Eppendorf ...
(Date:8/27/2014)... California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security LLC ... to develop and deliver a state-of-the-art laser system ... facility (ELI Beamlines), under construction in the Czech ... performance, the laser system, called the " High ...
Breaking Biology Technology:Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3
... right now. It's the new magic elixir that will solve ... swells. Then we'll go skipping off hand-in-hand through a sun-drenched ... was touting partnership just last week in this column, but ... the right relationship answer only if all involved are willing ...
... BLOOMFIELD HILLS, Mich. Logicalis , an international ... and storage solution providers, announced Monday it has acquired ... solution provider and one of IBM's top 10 Business ... also executed a letter of intent to purchase a ...
... advantage obsolete? Today, competitors can copy the newest ... or low-cost back-office process seemingly overnight. Indeed, it ... for long. This realization has led many corporate ... strategy to pursue is to create organizations that ...
Cached Biology Technology:Blooming partnerships 2Blooming partnerships 3Blooming partnerships 4Logicalis purchases Solution Technology for $90M 2Going beyond me, too customer experiences 2Going beyond me, too customer experiences 3Going beyond me, too customer experiences 4
(Date:8/28/2014)... traditional cigarettes, but still release toxins into the ... , Scientists studying secondhand smoke from e-cigarettes discovered ... particles, with close-to-zero exposure to organic carcinogens. However, ... second-hand e-cigarette smoke were found to be significantly ... of polycyclic aromatic hydrocarbons cancer-causing organic compounds ...
(Date:8/28/2014)... at the University of Minnesota have developed an animal ... used for muscle regeneration research as well as studies ... The research is published in the current edition of ... no treatment for FSHD, which is thought by many ... FSHD is an unusual genetic disorder because, unlike most ...
(Date:8/28/2014)... -- Scientists have identified the developmental on-off switch for ... produce more than two-thirds of the world,s naturally derived ... to see whether it is possible to manipulate this ... , The study, appearing August 28 in Cell ... molecule called cyclic-di-GMP and a larger protein called BldD ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2UMN researchers find animal model for understudied type of muscular dystrophy 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... of government from around the world today agreed at a ... fill a serious void in leadership related to global water ... nonexistent," the retired leaders say the panel will work to ... a looming "water crisis." The 20 members of the ...
... In the treeless, flat Prairie, you,d think a city would ... up and roost in trees and buildings. But researchers at ... urban landscape is far from ideal for these animals. ... lecturer and recent PhD graduate in biological sciences at the ...
... Institute scientists has found a key biological mechanism underpinning ... door to the development of drugs to manage excessive ... much of our lab,s research, was to examine the ... drinking driven by the aversive aspects of alcohol withdrawal," ...
Cached Biology News:Void in leadership on world water crisis cited by 20 former heads of government 2Big city holds empty promise for bats 2Scripps Research scientists find key mechanism in transition to alcohol dependence 2Scripps Research scientists find key mechanism in transition to alcohol dependence 3
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
... The Holten MaxiSafe 2010 Class II ... ergonomical working condition of comfort while ... efficiency and performance.,Refined operator, environment and ... both exhausted and recirculated air.,Bottom filters ...
... designed for paramagnetic bead precipitation from standard ... plates with no additional accessories. The stand ... standard SBS 96-well microplate footprint. The use ... easy and fast (as little as 30 ...
... unit ideal for use in laboratories with low ... set at 12 rpm , Temperature control ... capacity of four 35 x 150mm bottles, eight ... , Consistent, repeatable results achieved with microprocessor ...
Biology Products: